MCID: CRB039
MIFTS: 63

Cerebrovascular Disease

Categories: Cardiovascular diseases, Neuronal diseases

Aliases & Classifications for Cerebrovascular Disease

Summaries for Cerebrovascular Disease

Disease Ontology : 12 An artery disease that is characterized by dysfunction of the blood vessels supplying the brain.

MalaCards based summary : Cerebrovascular Disease, also known as cerebrovascular disorders, is related to ischemic heart disease and arthritis, and has symptoms including headache, transient ischemic attacks, stereotypic symptoms and angina pectoris. An important gene associated with Cerebrovascular Disease is NOTCH3 (Notch 3), and among its related pathways/superpathways are Metabolism of water-soluble vitamins and cofactors and Binding and Uptake of Ligands by Scavenger Receptors. The drugs Rivastigmine and Amiloride have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and testes, and related phenotypes are Decreased free cholesterol and Increased LDL uptake

Wikipedia : 72 A cerebrovascular disease is a vascular disease of the cerebral circulation. Arteries supplying oxygen... more...

Related Diseases for Cerebrovascular Disease

Diseases related to Cerebrovascular Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 284)
id Related Disease Score Top Affiliating Genes
1 ischemic heart disease 31.1 ACE CRP F2 SELP
2 arthritis 30.9 ACE APOE PON1
3 peripheral artery disease 30.7 ACE AGTR1 APOA1 APOB APOE CRP
4 stroke, ischemic 29.9 ACE AGTR1 APOB APOE CRP F2
5 myocardial infarction 27.8 ACE ADM AGTR1 APOA1 APOB APOE
6 basal ganglia cerebrovascular disease 11.9
7 carasil syndrome 11.4
8 autoimmune hemolytic anemia, warm type 11.1 ACE APOE
9 chronic fungal otitis externa 11.1 CRP F2
10 vascular dementia 11.1
11 primary pigmented nodular adrenocortical disease 11.0 COL4A1 F2 MTHFR
12 argyria 11.0 ACE F2
13 hypothyroidism due to iodide transport defect 11.0 ACE REN
14 fabry disease 11.0
15 pelvic inflammatory disease 11.0 ACE MTHFR NOTCH3
16 syncope 11.0 F2 MTHFR
17 cryptosporidiosis 11.0 F2 MTHFR SELP
18 dysgammaglobulinemia 11.0 F2 MTHFR SELP
19 thrombomodulin anomalies, familial 11.0 F2 MTHFR SELP
20 xk aprosencephaly 11.0 APOB APOE
21 lymphatic system cancer 11.0 F2 MTHFR PLAT
22 mediastinum leiomyoma 11.0 CRP F2 MTHFR
23 mechanical entropion 11.0 APOE PLAT
24 intestinal pseudo-obstruction 11.0 F2 MTHFR PLAT
25 chronic diarrhea due to guanylate cyclase 2c overactivity 11.0 ACE CRP PLAT
26 akinetic mutism 11.0 APOE APP CBS
27 prostate malignant phyllodes tumor 11.0 ACE CRP F2
28 primary hyperoxaluria 11.0 ACE REN
29 aryepiglottic fold cancer 11.0 F2 MTHFR PLAT
30 charcot-marie-tooth disease 11.0 APOE COL4A1 F2 MTHFR
31 homocystinuria due to mthfr deficiency 11.0 CBS MTHFR MTR
32 hypercholesterolemia, due to ligand-defective apo b 10.9 APOB APOE
33 thrombophilia due to activated protein c resistance 10.9 F2 MTHFR PLAT
34 iron metabolism disease 10.9 ACE APOE CRP SELP
35 capillary hemangioma 10.9 F2 MTHFR REN
36 hepatocellular adenoma 10.9 ACE CRP F2 MTHFR
37 myopia 10.9 ACE F2 REN
38 porphyria 10.9 F2 MTHFR
39 granulomatous hepatitis 10.9 CRP F2 SELP
40 spermatogenic failure 14 10.9 APOB CRP MTHFR
41 cystinosis 10.9 ACE CRP REN
42 homocystinuria 10.9 CBS MTHFR MTR
43 ectopic pregnancy 10.9 CBS MTHFR MTR
44 methylmalonic aciduria and homocystinuria type cblg 10.9 MTHFR MTR PON1
45 lockwood feingold syndrome 10.9 F2 MTHFR
46 adams-oliver syndrome 5 10.9 ACE CRP REN
47 mixed mineral dust pneumoconiosis 10.9 CRP F2 PLAT
48 superior limbic keratoconjunctivitis 10.9 F2 MTHFR
49 familial osteochondritis dissecans 10.9 APOA1 APOE
50 meckel's diverticulum 10.9 CRP F2 MTHFR PLAT

Comorbidity relations with Cerebrovascular Disease via Phenotypic Disease Network (PDN): (show all 40)


Active Peptic Ulcer Disease Acute Cystitis
Alzheimer Disease Anxiety Disorder
Basilar Artery Insufficiency Benign Essential Hypertension
Bronchitis Cerebral Atherosclerosis
Cerebral Degeneration Chronic Kidney Failure
Chronic Myocardial Ischemia Decubitus Ulcer
Deficiency Anemia Encephalopathy
Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation Esophagitis
Familial Atrial Fibrillation Generalized Atherosclerosis
Heart Disease Hypertension, Essential
Hypertensive Encephalopathy Hypothyroidism
Intermediate Coronary Syndrome Intracranial Embolism
Intracranial Thrombosis Iron Deficiency Anemia
Ischemic Heart Disease Labyrinthitis
Left Ventricular Outflow Tract Obstruction Malignant Essential Hypertension
Mitral Valve Disease Osteoporosis
Parkinson Disease, Late-Onset Peripheral Vascular Disease
Protein-Energy Malnutrition Schizophreniform Disorder
Sinoatrial Node Disease Swallowing Disorders
Transient Cerebral Ischemia Vertebral Artery Insufficiency

Graphical network of the top 20 diseases related to Cerebrovascular Disease:



Diseases related to Cerebrovascular Disease

Symptoms & Phenotypes for Cerebrovascular Disease

UMLS symptoms related to Cerebrovascular Disease:


headache, transient ischemic attacks, stereotypic symptoms, angina pectoris, back pain, chest pain, edema, pain, sciatica, seizures, syncope, tremor, chronic pain, vertigo/dizziness, equilibration disorder, sleeplessness

GenomeRNAi Phenotypes related to Cerebrovascular Disease according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased free cholesterol GR00340-A-2 9.26 APOA1 APOB APOE SELP
2 Increased LDL uptake GR00340-A-1 8.8 APOA1 APOE SELP

MGI Mouse Phenotypes related to Cerebrovascular Disease:

44 (show all 15)
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.45 ACE ACHE ADM AGTR1 APOA1 APOB
2 cardiovascular system MP:0005385 10.41 APOE COL4A1 CRP CX3CR1 F2 NOTCH3
3 behavior/neurological MP:0005386 10.36 ACE ACHE ADM AGTR1 APOE APP
4 growth/size/body region MP:0005378 10.36 ACE ACHE AGTR1 APOB APOE APP
5 hematopoietic system MP:0005397 10.31 ACE ACHE ADM AGTR1 APOE APP
6 mortality/aging MP:0010768 10.31 APOE APP COL4A1 CX3CR1 ACE ACHE
7 immune system MP:0005387 10.27 ACE ADM AGTR1 APOB APOE APP
8 cellular MP:0005384 10.26 ADM APOA1 APOB APOE APP COL4A1
9 nervous system MP:0003631 10.13 COL4A1 CX3CR1 F2 MTHFR NOTCH3 PLAT
10 integument MP:0010771 10.09 APP CX3CR1 F2 MTHFR NOTCH3 SELP
11 muscle MP:0005369 10.07 ACHE ADM APOB APOE APP COL4A1
12 reproductive system MP:0005389 9.97 ACE ACHE ADM APOB APOE APP
13 renal/urinary system MP:0005367 9.91 ACE ADM AGTR1 APOE COL4A1 CX3CR1
14 respiratory system MP:0005388 9.56 APOE COL4A1 F2 NOTCH3 PLAT SELP
15 vision/eye MP:0005391 9.28 ACHE APOB APOE COL4A1 CX3CR1 MTHFR

Drugs & Therapeutics for Cerebrovascular Disease

Drugs for Cerebrovascular Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 838)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Rivastigmine Approved, Investigational Phase 4,Phase 3 123441-03-2 77991
2
Amiloride Approved Phase 4 2016-88-8, 2609-46-3 16231
3
Amlodipine Approved Phase 4,Phase 3,Phase 2 88150-42-9 2162
4
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1 79902-63-9 54454
5
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
6
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1994-09-7, 94-09-7 2337
7
Nimodipine Approved Phase 4,Phase 3,Phase 1,Phase 2 66085-59-4 4497
8
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-78-2 2244
9
Pantoprazole Approved Phase 4,Phase 2 102625-70-7 4679
10
Ticlopidine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 55142-85-3 5472
11
Cilostazol Approved Phase 4,Phase 3,Phase 2 73963-72-1 2754
12
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3,Phase 2 58-93-5 3639
13
Perindopril Approved Phase 4,Phase 3 107133-36-8, 82834-16-0 107807
14
Candesartan Approved Phase 4,Phase 3 139481-59-7 2541
15
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1 59729-33-8 2771
16
Menthol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2216-51-5 16666
17
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-84-3 187
18
Rivaroxaban Approved Phase 4,Phase 2,Phase 3 366789-02-8
19
Atenolol Approved Phase 4,Phase 3 29122-68-7 2249
20
Valsartan Approved, Investigational Phase 4,Phase 2 137862-53-4 60846
21
Heparin Approved, Investigational Phase 4,Phase 2,Phase 3 9005-49-6 772 46507594
22 Nadroparin Approved Phase 4,Phase 3 9041-08-1
23
Zinc Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 7440-66-6 32051 23994
24
Azathioprine Approved Phase 4,Phase 3,Phase 2 446-86-6 2265
25
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2 50-18-0, 6055-19-2 2907
26
Clevidipine Approved Phase 4,Phase 3,Phase 2 167221-71-8
27
Nicardipine Approved Phase 4,Phase 3,Phase 2,Phase 1 55985-32-5 4474
28
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
29
alemtuzumab Approved, Investigational Phase 4 216503-57-0
30
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
31 Piracetam Approved Phase 4,Phase 3,Phase 1 7491-74-9
32
Everolimus Approved Phase 4,Phase 3,Phase 2 159351-69-6 6442177
33
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 22916-47-8 4189
34
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2 53123-88-9 5284616 6436030 46835353
35
Enalapril Approved, Vet_approved Phase 4,Phase 3,Phase 2 75847-73-3 5362032 40466924
36
Enalaprilat Approved Phase 4,Phase 3,Phase 2 76420-72-9 6917719
37
Rimonabant Approved, Investigational Phase 4,Phase 3 168273-06-1, 158681-13-1 104850
38
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
39
Nicotine Approved Phase 4 54-11-5 942 89594
40
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
41
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 76631-46-4, 113775-47-6 68602 5311068 56032
42
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 2078-54-8 4943
43
Warfarin Approved Phase 4,Phase 2,Phase 3,Phase 1 81-81-2 6691 54678486
44
Donepezil Approved Phase 4,Phase 3,Phase 1,Phase 2 120014-06-4 3152
45
Triamcinolone Approved, Vet_approved Phase 4,Phase 3 124-94-7 31307
46
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Early Phase 1 51-41-2 439260
47
Antipyrine Approved Phase 4,Phase 3,Phase 2,Phase 1 60-80-0 2206
48
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
49
Dalteparin Approved Phase 4,Phase 3,Phase 2 9005-49-6
50
Sevoflurane Approved, Vet_approved Phase 4,Phase 3,Phase 2 28523-86-6 5206

Interventional clinical trials:

(show top 50) (show all 4208)

id Name Status NCT ID Phase Drugs
1 Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVD Unknown status NCT02444637 Phase 4 Rivastigmine
2 Effects of Angiotensin II Receptor Blocker Compared With Diuretics in High-risk Hypertensive Patients Unknown status NCT01011660 Phase 4 Amlodipine, Telmisartan, Amiloride Compound , Simvastatin
3 Nimodipine for Treating Acute Massive Cerebral Infarction Unknown status NCT02248233 Phase 4 Nimodipine;Saline + citicoline
4 Study Effects of Ginkgo Biloba Extract on Endothelial Cell Function and Genetic Effects on the Response to Ginkgo Biloba Extract in Diabetic Patients With Stable Coronary Artery Disease Unknown status NCT01038050 Phase 4 Ginkgo Biloba Extract (GBE)
5 Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD? Unknown status NCT01621451 Phase 4 aspirin and/or clopidogrel;aspirin and/or clopidogrel
6 Cilostazol Versus Aspirin for Primary Prevention of Atherosclerotic Events Unknown status NCT00886574 Phase 4 Cilostazol;Aspirin
7 Rajavithi Health Promotion Project (Population Base Cohort) Unknown status NCT00368095 Phase 4
8 Cerebral Artery Stenosis, Coronary Artery Disease and Arrhythmia Unknown status NCT00247533 Phase 4
9 Evaluation of Efficacy and Safety of Agalsidase Beta in Heterozygous Females for Fabry Disease Unknown status NCT00487630 Phase 4 recombinant alpha-galactosidase A
10 Incidence of Acute Cerebrovascular Events Using Either Minimized or Standard Cardiopulmonary Bypass Circuit Unknown status NCT00862160 Phase 4
11 Stratification of Blood Pressure Control Against Progress of Cerebral Small Vessel Diseases in Poststroke Patients Unknown status NCT01819441 Phase 4 Azelnidipine;Perindopril;hydrochlorothiazide
12 Early Warning and Optimization Strategy in Carotid Endarterectomy Unknown status NCT01210937 Phase 4
13 SAPPHIRE Worldwide: Stenting and Angioplasty With Protection in Patients At High-Risk for Endarterectomy Unknown status NCT00403078 Phase 4
14 FINGER Robot Therapy Study Unknown status NCT02048826 Phase 4
15 Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST) Unknown status NCT00108706 Phase 4 Candesartan
16 Creative Therapy to Affect Stroke Outcomes Unknown status NCT01455155 Phase 4
17 A Clinical Trial of Danhong Injection in Treating Acute Ischemic Stroke Unknown status NCT02152280 Phase 4 Danhong Injection;Normal Saline
18 The Outcomes of Seamless ADL Training Between Occupational Therapist and Nurse in Stroke Patients Unknown status NCT02361307 Phase 4
19 4-point vs 4-roll Canne as Walking Aids After Stroke Unknown status NCT02279069 Phase 4
20 Multi-"Omics" Research of Danhong Injection to Treat Acute Ischemic Stroke Unknown status NCT02176395 Phase 4 Danhong injection;placebo
21 Effects on Clinical and Functional Outcome of Escitalopram in Adult Stroke Patients Unknown status NCT00967408 Phase 4 Escitalopram;Placebo
22 Functional Electrical Stimulation (FES) Assisted Walking: Enhancement of Walking Function After Stroke Unknown status NCT00552916 Phase 4
23 Efficacy and Safety Study of Nimodipine to Prevent Mild Cognitive Impairment After Acute Ischemic Strokes Unknown status NCT01220622 Phase 4 Nimodipine;Placebo
24 The Effectiveness and Safety of Butylphthalide Soft Capsules in Secondary Prevention of Ischemic Stroke Trial Unknown status NCT00724724 Phase 4 Butylphthalide Soft Capsules;Aspirin
25 Sleep Disordered Breathing in Transient Ischemic Attack (TIA)/Ischemic Stroke and Continuous Positive Airway Pressure (CPAP) Treatment Efficacy Unknown status NCT01097967 Phase 4
26 The Effectiveness of Early Botulinum Toxin A Injection for Lower Limbs Spasticity in Subacute Stroke Adults Unknown status NCT02505802 Phase 4 BoNT-A injection
27 Optimal Dose of Extracorporeal Shock Wave Therapy After Botulinum Toxin Type A Injection for Post-stroke Spasticity Unknown status NCT02358005 Phase 4
28 Evaluation of WATCHMAN Left Atrial Appendage Occlusion Device in Patients With Atrial Fibrillation Versus Rivaroxaban Unknown status NCT02549963 Phase 4 Rivaroxaban
29 Comprehensive Reparative Therapy in Ischemic Stroke COMplex Repair in Ischemic Stroke-Arm Unknown status NCT02581371 Phase 4 Cerebrolysin infusion
30 Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol Unknown status NCT02403349 Phase 4 Fimasartan;Valsartan;Atenolol
31 Safety Study of Melatonin in Stroke Patients Unknown status NCT01863277 Phase 4 Melatonin;placebo
32 Safety and Efficacy of Heparin and Nadroparin in the Acute Phase of Ischemic Stroke Unknown status NCT01862978 Phase 4 Heparin;Nadroparin;Placebo
33 Efficacy Study of Huatuo Zaizao Pills in Improving of Neural Function in Acute Ischemic Stroke Unknown status NCT01758536 Phase 4 Huatuo Zaizao Pills
34 Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Astragalus Membranaceus in the Patients After Stroke With Fatigue Unknown status NCT01554787 Phase 4 Chinese Herb Astragalus membranaceus
35 Valsartan Efficacy on Modest Blood Pressure Reduction in Acute Ischemic Stroke Unknown status NCT00874601 Phase 4 Diovan® (valsartan)
36 Comparison of Two Strategies for Glycemic Control in Acute Ischemic Stroke Unknown status NCT00747279 Phase 4 Intensive insulin therapy
37 Study of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer’s Disease, Vascular Dementia, and Mixed Vascular and Alzheimer’s Dementia Unknown status NCT00229333 Phase 4 Escitalopram
38 Clopidogrel and Atorvastatin Treatment During Carotid Artery Stenting Unknown status NCT01572623 Phase 4 Clopidogrel;Atorvastatin
39 The Preventive Effect of Escitalopram on Depression and Related Emotional Disorders in Acute Stroke Patients Unknown status NCT01278498 Phase 4 Escitalopram;sugar pill
40 CHUSPAN PAN BP Treatment of Polyarteritis Nodosa and Microscopic Polyangiitis Without Poor-Prognosis Factors Unknown status NCT00400075 Phase 4 azathioprine;cyclophosphamide
41 Comparison of Staged Angioplasty and Routine Single-stage Stenting (CAS) in the Treatment of Carotid Artery Stenosis Unknown status NCT02224209 Phase 4
42 The Role of Statins in Preventing Cerebral Vasospasm Secondary to Subarachnoid Hemorrhage Unknown status NCT01346748 Phase 4 statin
43 Treatment of Cranial Internal Carotid Artery Aneurysm With Willis Covered Stent and Coil Embolization Unknown status NCT01029938 Phase 4
44 The Efficacy and Safety of Cleviprex in Ventriculostomy Patients Requiring IV Antihypertensive Therapy Unknown status NCT01042574 Phase 4 Clevidipine butyrate
45 IV Double and Triple Concentrated Nicardipine for Stroke and ICH Unknown status NCT00325793 Phase 4 Nicardipine
46 The Dynamic Effect of Non-cytochrome P450 Isoenzyme 3A4(CYP3A4)-Metabolized and Cytochrome P450 Isoenzyme 3A4(CYP3A4)-Metabolized Statins on Clopidogrel Resistance in Patients With Cerebral Infarction Unknown status NCT02411903 Phase 4 atorvastatin and clopidogrel;rosuvastatin and clopidogrel
47 Steroids Pharmacokinetics and the Response to Prednisone Therapy in Giant Cell Arteritis Unknown status NCT01400464 Phase 4 Prednisone therapy and pharmacokinetic
48 Does Discontinuation of Aspirin Treatment Following Head Trauma Decrease the Incidence of Chronic Subdural Hematoma? Unknown status NCT01470040 Phase 4 discontinuation of aspirin therapy;continuation of aspirin therapy
49 HYdrogel Coil Versus Bare Platinum Coil in Recanalization Imaging Data Study Unknown status NCT01516658 Phase 4
50 Efficacy and Safety of BiomatrixTM Stent and 5mg-Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome Unknown status NCT02446730 Phase 4 Prasugel;Clopidogrel

Search NIH Clinical Center for Cerebrovascular Disease

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: stroke

Genetic Tests for Cerebrovascular Disease

Anatomical Context for Cerebrovascular Disease

MalaCards organs/tissues related to Cerebrovascular Disease:

39
Brain, Heart, Testes, Bone, Endothelial, Kidney, Cortex

Publications for Cerebrovascular Disease

Articles related to Cerebrovascular Disease:

(show top 50) (show all 811)
id Title Authors Year
1
Distinct white matter microstructural abnormalities and extracellular water increases relate to cognitive impairment in Alzheimer's disease with and without cerebrovascular disease. ( 28818116 )
2017
2
Increased Prevalence of Cerebrovascular Disease in Hospitalized Patients with Ehlers-Danlos Syndrome. ( 28647420 )
2017
3
Response by Bondonno et al to Letter Regarding Article, "Association of Vegetable Nitrate Intake With Carotid Atherosclerosis and Ischemic Cerebrovascular Disease in Older Women". ( 28830974 )
2017
4
Consensus statement on current and emerging methods for the diagnosis and evaluation of cerebrovascular disease. ( 28816594 )
2017
5
CPAP did not reduce cardiovascular events in patients with coronary or cerebrovascular disease and moderate to severe obstructive sleep apnoea. ( 28069600 )
2017
6
Depression and Cerebrovascular Disease: What is to be Done? ( 28011139 )
2017
7
Prospective Study on the Incidence of Cerebrovascular Disease After Coronary Angiography. ( 28855432 )
2017
8
Cerebrovascular Disease: Consequences of Obesity-Induced Endothelial Dysfunction. ( 28933065 )
2017
9
Prevention of Alzheimer's disease, cerebrovascular disease and dementia in women: the case for menopause hormone therapy. ( 28074678 )
2017
10
Relation between adiposity and vascular events, malignancy and mortality in patients with stable cerebrovascular disease. ( 28775374 )
2017
11
Letter by Tsuda Regarding Article, "Association of Vegetable Nitrate Intake With Carotid Atherosclerosis and Ischemic Cerebrovascular Disease in Older Women". ( 28830972 )
2017
12
Diabetes, Prediabetes, and Brain Volumes and Subclinical Cerebrovascular Disease on MRI: The Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS). ( 28916531 )
2017
13
Brain ureido degenerative protein modifications are associated with neuroinflammation and proteinopathy in Alzheimer's disease with cerebrovascular disease. ( 28865468 )
2017
14
Which antihypertensive drug should be used in patients with cerebrovascular disease to prevent a new stroke? ( 28069253 )
2017
15
Subclinical Cerebrovascular Disease Increases the Risk of Incident Stroke and Mortality: The Northern Manhattan Study. ( 28847914 )
2017
16
Cerebrovascular disease, associated risk factors and antithrombotic therapy in a population screening cohort: Insights from the Belgian Heart Rhythm Week programme. ( 27909151 )
2017
17
Effects of aspiration pneumonia on the intensive care requirements and in-hospital mortality of hospitalised patients with acute cerebrovascular disease. ( 28883847 )
2017
18
Prevention of Stroke in Patients With Silent Cerebrovascular Disease: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. ( 27980126 )
2017
19
A Decrease of Brain MicroRNA-122 Level Is an Early Marker of Cerebrovascular Disease in the Stroke-Prone Spontaneously Hypertensive Rat. ( 28751928 )
2017
20
Introducing Focused Updates in Cerebrovascular Disease. ( 28916676 )
2017
21
Impact of Birth Place and Geographic Location on Risk Disparities in Cerebrovascular Disease: Implications for Future Research. ( 28759684 )
2017
22
The burden of mood-disorder/cerebrovascular disease comorbidity: essential neurobiology, psychopharmacology, and physical activity interventions. ( 28681620 )
2017
23
Association of Blood Pressure Control Level With Left Ventricular Morphology and Function and With Subclinical Cerebrovascular Disease. ( 28757483 )
2017
24
The effectiveness and safety of dual antiplatelet therapy in ischemic cerebrovascular disease with intracranial and extracranial arteriostenosis in Chinese patients: A randomized and controlled trail. ( 28072691 )
2017
25
Social Cognition Deficits: Current Position and Future Directions for Neuropsychological Interventions in Cerebrovascular Disease. ( 28729755 )
2017
26
Use of antidepressants and the risk of cardiovascular and cerebrovascular disease: a meta-analysis of observational studies. ( 28070601 )
2017
27
Effects With and Without Clopidogrel Loading Treatment for Acute Ischemic Cerebrovascular Disease Patients: A Retrospective Cohort Study. ( 28826995 )
2017
28
Cardio-cerebrovascular disease and Helicobacter pylori-related metabolic syndrome: We consider eradication therapy as a potential cardio-cerebrovascular prevention strategy. ( 27887801 )
2017
29
Effects of high-intensity pulse irradiation with linear polarized near-infrared rays and stretching on muscle tone in patients with cerebrovascular disease: a randomized controlled trial. ( 28878481 )
2017
30
Antithrombotic therapy for secondary prevention of atherothrombotic events in cerebrovascular disease. ( 27489191 )
2016
31
Multiple neuropathologies and dementia in the aging brain: a key role for cerebrovascular disease? ( 28944284 )
2016
32
Is outdoor work associated with elevated rates of cerebrovascular disease mortality? A cohort study based on iron-ore mining. ( 27570536 )
2016
33
Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. ( 27465265 )
2016
34
CerefolinNAC Therapy ofA Hyperhomocysteinemia Delays Cortical and White Matter Atrophy in Alzheimer's Disease and Cerebrovascular Disease. ( 27567825 )
2016
35
Is the time ripe for new diagnostic criteria of cognitive impairment due to cerebrovascular disease? Consensus report of the International Congress on Vascular Dementia working group. ( 27806707 )
2016
36
Gender differences in white matter pathology and mitochondrial dysfunction in Alzheimer's disease with cerebrovascular disease. ( 26983404 )
2016
37
Impact of drinking and smoking habits on cerebrovascular disease risk among male employees. ( 27488512 )
2016
38
Validation of the Total Cerebrovascular Disease Burden Scale in a Community Sample. ( 27079726 )
2016
39
Imaging of cerebrovascular disease: a practical guide. ( 27852168 )
2016
40
Availability of endovascular therapies for cerebrovascular disease at primary stroke centers. ( 27895242 )
2016
41
Bacterial Endocarditis and Cerebrovascular Disease. ( 27815693 )
2016
42
Genetic Polymorphisms of Transcription Factor NRF2 and of its Host Gene Sulfiredoxin (SRXN1) are Associated with Cerebrovascular Disease in a Finnish Cohort, the TAMRISK Study. ( 27226772 )
2016
43
Cranial Magnetic Resonance Imaging in Elderly American Indians: Design, Methods, and Implementation of the Cerebrovascular Disease and Its Consequences in American Indians Study. ( 27603047 )
2016
44
Correction for Susceptibility Distortions Increases the Performance of Arterial Spin Labeling in Patients with Cerebrovascular Disease. ( 26902457 )
2016
45
Evaluation of image quality in carotid and cerebrovascular disease: a comparative study between subtraction and routine computed tomography angiography. ( 27528234 )
2016
46
Which Patients with Giant Cell Arteritis Will Develop Cardiovascular or Cerebrovascular Disease? A Clinical Practice Research Datalink Study. ( 27084910 )
2016
47
Aspirin resistance in cerebrovascular disease and the role of glycoprotein IIIa polymorphism in Turkish stroke patients. ( 26809135 )
2016
48
Helicobacter pylori eradication to prevent cardio-cerebrovascular disease: Are current data useful for clinical practice? ( 28043671 )
2016
49
Effect of galantamine on attention in patients with Alzheimer's disease combined with cerebrovascular disease. ( 27935239 )
2016
50
Long-term effects of pioglitazone on first attack of ischemic cerebrovascular disease in older people with type 2 diabetes: A case-control study in Taiwan. ( 27495077 )
2016

Variations for Cerebrovascular Disease

Expression for Cerebrovascular Disease

Search GEO for disease gene expression data for Cerebrovascular Disease.

Pathways for Cerebrovascular Disease

Pathways related to Cerebrovascular Disease according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.33 APOA1 APOB APOE MTHFR MTR
2
Show member pathways
11.47 APOA1 APOB APOE COL4A1
3
Show member pathways
11.41 APOA1 APOB APOE
4 11.36 ACE AGTR1 REN
5 11.11 APOB PLAT SELP
6 10.55 ACE APP PLAT
7 10.47 ACE APOE APP CX3CR1
8
Show member pathways
10.39 CBS MTHFR

GO Terms for Cerebrovascular Disease

Cellular components related to Cerebrovascular Disease according to GeneCards Suite gene sharing:

(show all 13)
id Name GO ID Score Top Affiliating Genes
1 blood microparticle GO:0072562 9.81 APOA1 APOE F2 PON1
2 extracellular region GO:0005576 9.8 ACE ACHE ADM APOA1 APOB APOE
3 endoplasmic reticulum lumen GO:0005788 9.73 APOA1 APOB APOE APP COL4A1 F2
4 apical part of cell GO:0045177 9.7 APP PLAT REN
5 high-density lipoprotein particle GO:0034364 9.63 APOA1 APOE PON1
6 very-low-density lipoprotein particle GO:0034361 9.61 APOA1 APOB APOE
7 endocytic vesicle lumen GO:0071682 9.58 APOA1 APOB APOE
8 low-density lipoprotein particle GO:0034362 9.54 APOA1 APOB APOE
9 chylomicron GO:0042627 9.5 APOA1 APOB APOE
10 spherical high-density lipoprotein particle GO:0034366 9.49 APOA1 PON1
11 extracellular space GO:0005615 9.47 ACE ACHE ADM APOA1 APOB APOE
12 intermediate-density lipoprotein particle GO:0034363 9.33 APOA1 APOB APOE
13 discoidal high-density lipoprotein particle GO:0034365 9.18 APOA1

Biological processes related to Cerebrovascular Disease according to GeneCards Suite gene sharing:

(show all 34)
id Name GO ID Score Top Affiliating Genes
1 response to lipopolysaccharide GO:0032496 9.9 ADM APOB REN SELP
2 cellular protein metabolic process GO:0044267 9.85 APOA1 APOB APOE APP F2
3 response to organic substance GO:0010033 9.84 ADM APOB REN
4 cholesterol homeostasis GO:0042632 9.79 APOA1 APOB APOE
5 retinoid metabolic process GO:0001523 9.78 APOA1 APOB APOE
6 response to wounding GO:0009611 9.73 ACHE ADM CX3CR1 F2
7 triglyceride catabolic process GO:0019433 9.7 APOA1 APOB APOE
8 cholesterol efflux GO:0033344 9.69 APOA1 APOB APOE
9 lipoprotein metabolic process GO:0042157 9.67 APOA1 APOB APOE
10 positive regulation of cholesterol efflux GO:0010875 9.66 APOE PON1
11 beta-amyloid metabolic process GO:0050435 9.65 ACE REN
12 regulation of blood vessel diameter GO:0097746 9.65 ACE AGTR1
13 high-density lipoprotein particle assembly GO:0034380 9.65 APOA1 APOE
14 artery morphogenesis GO:0048844 9.65 APOB APOE NOTCH3
15 phospholipid efflux GO:0033700 9.64 APOA1 APOE
16 angiotensin maturation GO:0002003 9.64 ACE REN
17 amyloid precursor protein metabolic process GO:0042982 9.63 ACHE APOE
18 negative regulation of platelet activation GO:0010544 9.63 APOE F2
19 high-density lipoprotein particle clearance GO:0034384 9.62 APOA1 APOE
20 chylomicron remnant clearance GO:0034382 9.61 APOB APOE
21 regulation of Cdc42 protein signal transduction GO:0032489 9.59 APOA1 APOE
22 negative regulation of long-term synaptic potentiation GO:1900272 9.58 APOE CX3CR1
23 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.58 ACE AGTR1
24 low-density lipoprotein particle remodeling GO:0034374 9.58 AGTR1 APOB APOE
25 homocysteine metabolic process GO:0050667 9.57 CBS MTHFR
26 very-low-density lipoprotein particle clearance GO:0034447 9.56 APOB APOE
27 renin-angiotensin regulation of aldosterone production GO:0002018 9.55 AGTR1 REN
28 lipoprotein catabolic process GO:0042159 9.54 APOB APOE
29 chylomicron assembly GO:0034378 9.54 APOA1 APOB APOE
30 positive regulation of cholesterol esterification GO:0010873 9.5 AGTR1 APOA1 APOE
31 chylomicron remodeling GO:0034371 9.43 APOA1 APOB APOE
32 neuron projection regeneration GO:0031102 9.33 ADM APOA1 APOE
33 lipoprotein biosynthetic process GO:0042158 9.13 APOA1 APOB APOE
34 cholesterol metabolic process GO:0008203 9.02 APOA1 APOB APOE APP PON1

Molecular functions related to Cerebrovascular Disease according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 receptor binding GO:0005102 9.89 ADM APP F2 PLAT REN
2 beta-amyloid binding GO:0001540 9.65 ACHE APOA1 APOE
3 phospholipid binding GO:0005543 9.56 APOA1 APOB APOE PON1
4 lipid transporter activity GO:0005319 9.5 APOA1 APOB APOE
5 modified amino acid binding GO:0072341 9.46 CBS MTHFR
6 lipoprotein particle binding GO:0071813 9.43 APOA1 APOE
7 phosphatidylcholine-sterol O-acyltransferase activator activity GO:0060228 9.4 APOA1 APOE
8 bradykinin receptor binding GO:0031711 9.37 ACE AGTR1
9 low-density lipoprotein particle receptor binding GO:0050750 9.33 APOB APOE CRP
10 cholesterol transporter activity GO:0017127 9.13 APOA1 APOB APOE
11 heparin binding GO:0008201 9.02 APOB APOE APP F2 SELP

Sources for Cerebrovascular Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....